The potential of antibody-mediated immunity in the defence against biological weapons

Arturo Casadevall; Liise Anne Pirofski

doi:10.1517/14712598.5.10.1359

The potential of antibody-mediated immunity in the defence against biological weapons

Arturo Casadevall, Liise Anne Pirofski

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Antibody-mediated immunity (AMI) has been used for the treatment and prevention of infectious diseases for > 100 years, and has a remarkable record of safety, efficacy and versatility. AMI can be used for defence against a wide variety of biological weapons, and passive antibody (Ab) therapy has the potential to provide immediate immunity to susceptible individuals. Recent advances in the Ab field make it possible to generate Abs with enhanced antimicrobial functions. There are significant gaps in our understanding of Ab function, such that the development of Ab-based strategies remains a largely empirical exercise. Nevertheless, the advantages inherent in the therapeutic and prophylactic use of AMI provide a powerful rationale for continued development that will undoubtedly yield many new vaccines and therapeutic Abs.

Original language	English (US)
Pages (from-to)	1359-1372
Number of pages	14
Journal	Expert Opinion on Biological Therapy
Volume	5
Issue number	10
DOIs	https://doi.org/10.1517/14712598.5.10.1359
State	Published - Oct 2005
Externally published	Yes

Keywords

Antibody
Bioterrorism
Humoral
Immunoglobulin
Vaccine

ASJC Scopus subject areas

Pharmacology
Drug Discovery
Clinical Biochemistry

Access to Document

10.1517/14712598.5.10.1359

Cite this

@article{2b83b95167b24f6899fb8b1c7585cc56,

title = "The potential of antibody-mediated immunity in the defence against biological weapons",

abstract = "Antibody-mediated immunity (AMI) has been used for the treatment and prevention of infectious diseases for > 100 years, and has a remarkable record of safety, efficacy and versatility. AMI can be used for defence against a wide variety of biological weapons, and passive antibody (Ab) therapy has the potential to provide immediate immunity to susceptible individuals. Recent advances in the Ab field make it possible to generate Abs with enhanced antimicrobial functions. There are significant gaps in our understanding of Ab function, such that the development of Ab-based strategies remains a largely empirical exercise. Nevertheless, the advantages inherent in the therapeutic and prophylactic use of AMI provide a powerful rationale for continued development that will undoubtedly yield many new vaccines and therapeutic Abs.",

keywords = "Antibody, Bioterrorism, Humoral, Immunoglobulin, Vaccine",

author = "Arturo Casadevall and Pirofski, {Liise Anne}",

note = "Funding Information: AC was supported by NIH grant AI057158-03. LP was supported by NIH grants AI35370, AI45459, AI44374.",

year = "2005",

month = oct,

doi = "10.1517/14712598.5.10.1359",

language = "English (US)",

volume = "5",

pages = "1359--1372",

journal = "Expert Opinion on Biological Therapy",

issn = "1471-2598",

publisher = "Informa Healthcare",

number = "10",

}

TY - JOUR

T1 - The potential of antibody-mediated immunity in the defence against biological weapons

AU - Casadevall, Arturo

AU - Pirofski, Liise Anne

N1 - Funding Information: AC was supported by NIH grant AI057158-03. LP was supported by NIH grants AI35370, AI45459, AI44374.

PY - 2005/10

Y1 - 2005/10

N2 - Antibody-mediated immunity (AMI) has been used for the treatment and prevention of infectious diseases for > 100 years, and has a remarkable record of safety, efficacy and versatility. AMI can be used for defence against a wide variety of biological weapons, and passive antibody (Ab) therapy has the potential to provide immediate immunity to susceptible individuals. Recent advances in the Ab field make it possible to generate Abs with enhanced antimicrobial functions. There are significant gaps in our understanding of Ab function, such that the development of Ab-based strategies remains a largely empirical exercise. Nevertheless, the advantages inherent in the therapeutic and prophylactic use of AMI provide a powerful rationale for continued development that will undoubtedly yield many new vaccines and therapeutic Abs.

AB - Antibody-mediated immunity (AMI) has been used for the treatment and prevention of infectious diseases for > 100 years, and has a remarkable record of safety, efficacy and versatility. AMI can be used for defence against a wide variety of biological weapons, and passive antibody (Ab) therapy has the potential to provide immediate immunity to susceptible individuals. Recent advances in the Ab field make it possible to generate Abs with enhanced antimicrobial functions. There are significant gaps in our understanding of Ab function, such that the development of Ab-based strategies remains a largely empirical exercise. Nevertheless, the advantages inherent in the therapeutic and prophylactic use of AMI provide a powerful rationale for continued development that will undoubtedly yield many new vaccines and therapeutic Abs.

KW - Antibody

KW - Bioterrorism

KW - Humoral

KW - Immunoglobulin

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=27144497271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144497271&partnerID=8YFLogxK

U2 - 10.1517/14712598.5.10.1359

DO - 10.1517/14712598.5.10.1359

M3 - Review article

C2 - 16197341

AN - SCOPUS:27144497271

SN - 1471-2598

VL - 5

SP - 1359

EP - 1372

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

IS - 10

ER -

The potential of antibody-mediated immunity in the defence against biological weapons

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this